Fixed dose rivaroxaban can be used in extremes of bodyweight: A population pharmacokinetic analysis ‐ Reply to Jacobs & Ryan comment
- 2 March 2021
- journal article
- letter
- Published by Elsevier BV in Journal of Thrombosis and Haemostasis
- Vol. 19 (3), 872-873
- https://doi.org/10.1111/jth.15196
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- UK real-world experience of prescribing rivaroxaban for acute venous thromboembolism in obesity: Results from the FIRST RegistryThrombosis Research, 2020
- Effectiveness and safety of apixaban and rivaroxaban for acute venous thromboembolism therapy in patients with extremes in bodyweightEuropean Journal of Haematology, 2020
- Fixed dose rivaroxaban can be used in extremes of bodyweight: A population pharmacokinetic analysisJournal of Thrombosis and Haemostasis, 2020
- Anticoagulant therapies and outcomes in obese patients with acute venous thromboembolismThrombosis Research, 2020
- Rivaroxaban versus warfarin treatment among morbidly obese patients with venous thromboembolism: Comparative effectiveness, safety, and costsThrombosis Research, 2019
- Comparative effectiveness, safety, and costs of rivaroxaban and warfarin among morbidly obese patients with atrial fibrillationAmerican Heart Journal, 2019
- Integrated Population Pharmacokinetic Analysis of Rivaroxaban Across Multiple Patient PopulationsCPT: Pharmacometrics & Systems Pharmacology, 2018
- Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTHJournal of Thrombosis and Haemostasis, 2016
- Body Weight Has Limited Influence on the Safety, Tolerability, Pharmacokinetics, or Pharmacodynamics of Rivaroxaban (BAY 59‐7939) in Healthy SubjectsThe Journal of Clinical Pharmacology, 2007